Humacyte, Inc.
General ticker "HUMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $226.5M (TTM average)
Humacyte, Inc. does not follow the US Stock Market performance with the rate: -21.1%.
Estimated limits based on current volatility of 4.4%: low 1.37$, high 1.49$
Factors to consider:
- Total employees count: 185 (+12.8%) as of 2023
- Top business risk factors: Operational and conduct risks, Clinical trial success, Regulatory and compliance, Manufacturing scale up, Manufacturing risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.75$, 2.25$]
- 2026-12-31 to 2027-12-31 estimated range: [0.96$, 2.65$]
Financial Metrics affecting the HUMA estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.53 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term HUMA quotes
Long-term HUMA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $2.04MM |
| Operating Expenses | $100.05MM | $114.40MM | $110.17MM |
| Operating Income | $-100.05MM | $-114.40MM | $-108.14MM |
| Non-Operating Income | $-10.73MM | $-34.30MM | $67.30MM |
| Interest Expense | $6.60MM | $9.28MM | $11.25MM |
| R&D Expense | $76.55MM | $88.60MM | $69.30MM |
| Income(Loss) | $-110.78MM | $-148.70MM | $-40.83MM |
| Net Income(Loss)* | $-110.78MM | $-148.70MM | $-40.83MM |
| Stockholders Equity | $13.55MM | $-52.67MM | $3.11MM |
| Inventory | $0.00MM | $0.00MM | $13.59MM |
| Assets | $128.22MM | $137.87MM | $116.37MM |
| Operating Cash Flow | $-73.31MM | $-98.12MM | $-105.04MM |
| Capital expenditure | $2.28MM | $1.57MM | $0.88MM |
| Investing Cash Flow | $-0.17MM | $-1.57MM | $-0.88MM |
| Financing Cash Flow | $4.51MM | $114.18MM | $61.49MM |
| Earnings Per Share** | $-1.07 | $-1.26 | $-0.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.